Article Details
Retrieved on: 2021-06-05 06:45:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
ENZC is a pioneer in using monoclonal antibodies for treating COVID-19. A break over $0.958 and its blue skies ahead for ENZC. ENZC has ...
Article found on: microcapdaily.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here